Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
2.

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B.

Clin Cancer Res. 2014 Dec 15;20(24):6295-303. doi: 10.1158/1078-0432.CCR-14-1373. Epub 2014 Oct 16.

3.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM.

J Clin Oncol. 2001 Oct 1;19(19):3918-28.

PMID:
11579112
4.

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS.

J Clin Oncol. 2000 Mar;18(6):1316-23.

PMID:
10715303
5.

Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.

Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):339-44.

PMID:
9525435
6.

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.

Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS.

Ann Intern Med. 1997 Feb 15;126(4):257-63.

PMID:
9036797
7.

A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).

Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL.

Adv Exp Med Biol. 1996;394:105-15. Review. No abstract available.

PMID:
8815677
8.
9.

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.

Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ.

Cancer. 1993 Jun 1;71(11):3601-4.

PMID:
8490909
10.

Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump.

Frye JW, Venook AP, Ostroff JW, Mulvihill SJ, Warren RS, Pellegrini CA, Ring EJ, Stagg RJ.

Gastrointest Endosc. 1992 Jan-Feb;38(1):52-4. No abstract available.

PMID:
1612381
11.

Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.

Stagg RJ, Venook AP, Chase JL, Lewis BJ, Warren RS, Roh M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC.

J Natl Cancer Inst. 1991 Mar 20;83(6):423-8.

PMID:
1825674
12.

Chemoembolization for hepatocellular carcinoma.

Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC.

J Clin Oncol. 1990 Jun;8(6):1108-14.

PMID:
2161449
13.

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, Acord P, Lewis BJ.

J Clin Oncol. 1989 Nov;7(11):1646-54.

PMID:
2530317
14.

Regional chemotherapy for colorectal cancer metastatic to the liver.

Venook AP, Stagg RJ, Lewis BJ.

Oncology (Williston Park). 1988 Mar;2(3):19-26. Review. Erratum in: Oncology (Williston Park) 1988 May;2(5):15.

PMID:
3079322
15.

Total hepatic arterial perfusion after occlusion of variant lobar vessels: implications for hepatic arterial chemotherapy.

Rayner AA, Kerlan RK, Stagg RJ, Price DC, Hohn DC.

Surgery. 1986 Jun;99(6):708-15.

PMID:
3715718
16.

Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion.

Hohn DC, Rayner AA, Economou JS, Ignoffo RJ, Lewis BJ, Stagg RJ.

Cancer. 1986 Feb 1;57(3):465-70.

PMID:
2935242
17.

Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine.

Hohn DC, Stagg RJ, Price DC, Lewis BJ.

J Clin Oncol. 1985 Sep;3(9):1257-60.

PMID:
3162003
18.

Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.

Barriere SL, Gambertoglio JG, Alexander DP, Stagg RJ, Conte JE Jr.

Rev Infect Dis. 1984 Nov-Dec;6 Suppl 4:S809-15.

PMID:
6522922
19.

Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.

Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DC.

Ann Intern Med. 1984 May;100(5):736-43. Review.

PMID:
6231876
20.

Quantitation of cell-mediated immunity: responses to dinitrochlorobenzene and ubiquitous antigens.

Thompson CD, Whittingham S, Mackay IR, Khoo SK, Toh BH, Stagg RJ.

Can Med Assoc J. 1975 May 3;112(9):1078-81.

Supplemental Content

Loading ...
Support Center